Brainstorm Cell Therapeutics Inc.
OTCPKBrainstorm Cell Therapeutics heads into the weekend with a sharp dislocation in its lending market — cost to borrow has more than doubled in a week — even as short sellers hold a position that is tiny relative to the float. The most striking data point right now is in the borrow market, not the short book. Cost to borrow has climbed to 10.37%, up 146% week-on-week and nearly double…
BCLI cost to borrow surges to 10.37% — up 146% over the past week, a dramatic spike in borrowing costs for the micro-cap biotech.
Snapshot as of 16 May 2026
Brainstorm Cell Therapeutics heads into the weekend with a sharp dislocation in its lending market — cost to borrow has more than doubled in a week — even as short sellers hold a position that is tiny relative to the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BCLI — free to start on ORTEX.
Sign up for free →Open BCLI on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live BCLI data →